Abstract 2311
Background
EGFR mutations are associated with variable response to EGFR-TKI depending on the types of exons, mutations or clinical characteristics. To better understand these features we reviewed all cases of EGFR mutated NSCLC collected in the Biomarkers France database (Barlesi et al, Lancet 2016).
Methods
Among the 17,664 patients, 1837 (10.3%) with an EGFR mutated NSCLC were analyzed for their biological and clinical characteristics.
Results
EGFR exon 18, 19, 20 and 21 mutations were found in 102 (5.6%), 931 (50.6%), 102 (5.6%) and 702 (38.2%) patients among which 70 had never been described. Proportion of smokers was higher in exon 18 (20%) and exon 20 (19%) compared to exon 19 (11%) and 21 (11%) (p = 0.002). Personal history of cancer was related in 226 patients (19.2%), irrespective of the exons. T790M mutated patients (n = 42) were excluded for survival analysis. Median follow-up was 36.7 [36.4-37] months. Median overall survivals (OS), first-line progression-free survivals (PFS) and disease control rates (DCR) under first-line EGFR-TKI according to the type of EGFR mutation are summarized in table 1. Median OS was longer for exon 19 deletions compared to L858R mutations (26.5 vs. 21.3 months, p = 0.045). In exon 19, there was no difference in OS based on the length of the deletion. In exon 21, median OS was longer for L858R than for L861Q or other substitutions or wild-type (22.4 vs. 14.1 vs. 14.9 vs. 11.8, p =
Conclusions
Common and non-common EGFR mutations presented different clinical characteristics. Among common mutations, exon 19 mutated patients had better outcomes.
Clinical trial identification
NCT01700582
Legal entity responsible for the study
N/A
Funding
INCa, AstraZeneca
Disclosure
C. Leduc: Chugai. M. Beau-Faller: AstraZeneca, Boerhinger-Ingelheim, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
Top-line results from SUNRISE: A phase III, randomized, double-blind, placebo-controlled multicenter trial of bavituximab plus docetaxel in patients with previously treated stage IIIb/iv non-squamous non-small cell lung cancer
Presenter: David Spigel
Session: NSCLC, metastatic 2
Resources:
Abstract
Presentation
Selumetinib in combination with docetaxel as second-line treatment for patients with KRAS-mutant advanced NSCLC: Results from the phase III SELECT-1 trial
Presenter: Pasi Jänne
Session: NSCLC, metastatic 2
Resources:
Abstract
Presentation
Invited discussant LBA45, LBA47_PR and abstract 1202O
Presenter: Tony S.K. Mok
Session: NSCLC, metastatic 2
Resources:
Presentation